The Swedish company Galecto Biotech AB is to merge with PharmAkea Inc of San Diego, US in order to build critical mass in the fields of fibrosis and cancer. Galecto has a pipeline of drug candidates targeting galectin-3, a protein linked with organ fibrosis. Financial details of the merger were not disclosed.
